SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

SLONIN JONATHAN

(Last)

(First)

(Middle)

C/O PACIRA BIOSCIENCES, INC.

5401 WEST KENNEDY BOULEVARD, SUITE 890

(Street)

TAMPA

33609

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/06/2023

3. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	45,884.94⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾	06/14/2033	Common Stock	27,500	$38.74	D
Stock Option (Right to Buy)	⁽²⁾	06/08/2032	Common Stock	24,800	$59.39	D
Stock Option (Right to Buy)	⁽²⁾	08/03/2031	Common Stock	10,000	$60.79	D
Stock Option (Right to Buy)	⁽²⁾	06/09/2031	Common Stock	14,137	$60.96	D
Stock Option (Right to Buy)	⁽²⁾	07/02/2030	Common Stock	35,500	$52.37	D

Explanation of Responses:

1. Includes 27,452 unvested restricted stock units. The unvested restricted stock units vest as follows: (i) 10,950 restricted stock units that vest in four equal annual installments on June 3, 2024, June 3, 2025, June 3, 2025 and June 3, 2026; (ii) 7,425 restricted stock units that vest in three equal annual installments on June 3, 2024, June 3, 2025 and June 3, 2026; (iii) 2,500 restricted stock units that vest in two equal annual installments on August 1, 2024 and August 1, 2025; (iv) 2,827 restricted stock units that vest in two equal annual installments on June 3, 2024 and June 3, 2025; and (v) 3,750 restricted stock units that vest on July 1, 2024; in each case provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

2. The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Remarks:

Although the reporting person was previously deemed to be an "officer" of the issuer for purposes of Section 16, the issuer's board of directors (the "board") determined, at a meeting held on June 14, 2023, that the reporting person should no longer be designated a Section 16 "officer." However, in connection with his expected performance of certain significant policy-making functions for the issuer as a result of his promotion to Chief Medical Officer on December 5, 2023, the board determined, at a meeting held on December 6, 2023, that the reporting person should once again be designated a Section 16 "officer" of the issuer. As a result, the reporting person is filing this Initial Statement of Beneficial Ownership of Securities on Form 3.

	/s/ Kristen Williams, Attorney-in-Fact	12/07/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.